Abstract. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively kills various types of cancer cells without harming normal cells, but TRAIL resistance has been frequently observed in cancer cells. Propolis (bee glue) is a material collected from various plants by honeybees and is a rich source of bioactive compounds, including the natural flavonoid chrysin, which possesses multiple anticancer effects. We investigated the mechanism underlying the TRAIL sensitization effect of chrysin, which is a major constituent of Thai propolis, in human lung and cervical cancer cell lines. Propolis extract and chrysin sensitizes A549 and HeLa human cancer cell lines to TRAIL-induced apoptosis. The TRAIL sensitization effect of chrysin is not mediated by inhibition of TRAIL-induced NF-κB activation or by glutathione depletion. Immunoblot analysis using a panel of anti-apoptotic proteins revealed that chrysin selectively decreases the levels of Mcl-1 protein, by downregulating Mcl-1 gene expression as determined by qRT-PCR. The contribution of Mcl-1 in TRAIL resistance was confirmed by si-Mcl-1 knockdown. Among signaling pathways that regulate Mcl-1 gene expression, only constitutive STAT3 phosphorylation was suppressed by chrysin. The proposed action of chrysin in TRAIL sensitization by inhibiting STAT3 and downregulating Mcl-1 was supported by using a STAT3-specific inhibitor, cucurbitacin-I, which decreased Mcl-1 levels and enhanced TRAIL-induced cell death, similar to that observed with chrysin treatment. In conclusion, we show the potential of chrysin in overcoming TRAIL resistance of cancer cells and elucidate its mechanism of action.
Introduction
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a transmembrane protein expressed on surface of several types of immune cells (1, 2) . TRAIL is a member of tumor necrosis factor (TNF) family, and has recently received much attention because it selectively induces apoptosis in various cancer types without toxic effect to normal cells, independently of growth rate and p53 status of the cancer cells (2) . TRAIL triggers apoptosis upon binding to its death receptors, DR4/TRAIL-R1 or DR5/TRAIL-R2, leading to activation of caspase-8 which further activates caspase-3. In some cell types, TRAIL-induced apoptosis requires contribution of the mitochondrial pathway activated by caspase-8-mediated Bid cleavage (1) . Clinical trials, using recombinant soluble TRAIL or agonistic monoclonal antibodies (mAb) targeting TRAIL receptors, are being investigated for cancer therapy, either as monotherapy or in combination with other drugs (3) . The appearance of TRAIL resistance has been observed in many cancer cell lines and primary tumor cells, and may be due to defects in TRAIL receptor signaling or dysregulation of anti-apoptotic proteins controlled by survival signaling pathways which are occasionally over-activated in cancer (4) . Currently, there is much interest in searching for natural products that overcome TRAIL resistance for use during TRAIL treatment (5) .
Propolis (bee glue) is a resinous material collected from various plants by honeybees for use as a defense against pathogenic microorganisms, and is attractive for pharmacological research as a rich source of bioactive compounds (6) . Propolis extract has been shown to enhance TRAIL-induced apoptosis (7) . However, the bioactivity and chemical composi-tion of propolis varies with geographic location (6, 8, 9) . Chrysin (5,7-dihydroxyflavone) is a flavonoid found in some propolis extracts and in plants (10) . There is increasing evidence of potential benefits of chrysin as a pharmacological agent. Diverse anticancer effects and mechanisms have been reported for chrysin, including inducing apoptosis by Akt inhibition (11) , inducing cell cycle arrest through p38-MAPK activation (12) , and enhancing cytotoxicity of chemotherapeutic drugs via cellular glutathione depletion (13, 14) . Chrysin was shown to sensitize HCT-116 human colorectal cancer cells to TNFα-induced apoptosis, by inhibiting TNFα-induced NF-κB activation and preventing expression of FLIP L anti-apoptotic protein which is an NF-κB target gene (15) . Chrysin appears to enhance TRAIL-induced apoptosis in variety of human cancer cell lines originating from different organs including colorectal cancer, cervical cancer, hepatocellular carcinoma and nasopharyngeal carcinoma, suggesting that chrysin may have potential as a TRAIL sensitizer (16) . However, until now, the mechanism for TRAIL sensitization effect of chrysin is still not known.
The mechanism of a TRAIL sensitizing agent should be clear before further study on using it in combination treatment with TRAIL or agonistic mAb targeting TRAIL receptors in clinical trials. Therefore, this study investigated the mechanism underlying the TRAIL sensitization effect of chrysin in TRAIL resistant human cancer cell lines, by determining the involvement of NF-κB activation, glutathione depletion, and levels of anti-apoptotic proteins in TRAIL sensitization, and further exploring the contributing signaling pathways.
Materials and methods
Propolis extraction and isolation of compounds. Propolis was collected from a hive of Apis mellifera from Chiangmai province, Thailand, in August 2006. A voucher specimen (SWU 0212) was deposited at the Faculty of Pharmacy, Srinakharinwirot University, Nakhon Nayok province, Thailand. Thai propolis (1 kg) was extracted by sonication with methanol (2 liters, 90 min x 3) at room temperature. Removal of methanol yielded the methanol extract (517 g). Part of the methanol extract (140 g) was subjected to silica gel column chromatography using dichloromethane, with increasing concentration of methanol, give 16 fractions. Chrysin (732 mg) and tectochrysin (314 mg) were isolated by crystallization from fractions. Chrysin and tectochrysin were identified by comparison of physical and spectroscopic data with authentic standard and literature values (17, 18) .
Reagents and antibodies.
Recombinant human TRAIL and recombinant human tumor necrosis factor (TNF)-α were purchased from Peprotech (London, UK). Curcumin was obtained from Fluka Chemika (Steinheim, Switzerland). N-acetylcysteine (NAC) and 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and chrysin were purchased from Sigma-Aldrich (St. Louis, MO). STAT3 specific inhibitor (cucurbitacin-I) and IKK-2 inhibitor IV were obtained from Calbiochem (San Diego, CA). Lipofectamine 2000 reagent and hygromycin B were purchased from Invitrogen (Carlsbad, CA). Test compounds were dissolved in dimethyl sulfoxide (DMSO) and kept as a stock solution at -20˚C. The final concentration of DMSO was kept below 0.2% throughout the study. Cell culture. A549 human lung adenocarcinoma and HeLa human cervical carcinoma are TRAIL resistant cell lines (19) . Cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, MD). A549 was cultured in RPMI-1640 supplemented with 10% fetal bovine serum (FBS), 100 U/ml of penicillin and 100 µg/ml of streptomycin. HeLa was cultured in DMEM supplemented with 2 mM L-glutamine, 10% FBS and the antibiotics. The cells were maintained at 37˚C in a humidified atmosphere of 5% CO 2 .
Cell viability assay. Cell viability after treatment was determined by MTT method (20) . Briefly, cells in 96-well plates (100 µl/well) were pretreated by adding medium (100 µl) containing test compound to the wells, and incubated for 30 min, then aliquots of TRAIL in medium (5 µl) were added to each well (final concentration of 100 ng/ml for A549 cells, or 200 ng/ml for HeLa cells), and further incubated for 24 h. Then, the wells were replaced and incubated with fresh culture media containing MTT (0.5 mg/ml) for 2 h at 37˚C. Finally, the media were removed and DMSO (100 µl) was added to the wells, and absorbance was measured at 550 nm in a microplate reader, subtracted with absorbance at 650 nm. The number of viable cells was determined from the absorbance. Assays were performed in triplicate wells. Data were expressed as percent viability compared with control.
Establishment of stable NF-κB reporter cell line. A549 cells were transfected with pGL4.32[luc2P/NF-κB-RE/Hygro] vector (Promega, Madison, WI) using Lipofectamine 2000 reagent according to manufacturer's protocol. After transfection for 24 h, the transfected cells were selected by sub-culturing into new flasks containing RPMI-1640 supplemented with 10% FBS and 800 µg/ml hygromycin B and maintained in this media over 2 weeks to obtain the stable transfected cells (A549/NF-κB).
NF-κB transcriptional activity assay. NF-κB transcriptional activity was determined by luciferase reporter gene assay. A549/NF-κB cells were seeded into a 96-well plate (100 µl/well), and left overnight. Cells were pretreated with test compound (100 µl) for 30 min, followed by adding 5 µl of medium containing TNFα or TRAIL, and further incubated for 3 h. Cells were then lysed with 25 µl of passive lysis buffer (Promega), and 20 µl of cell lysate was mixed with 50 µl of luciferase assay reagent (Promega). Luminescence was determined using a luminometer (Atto, Tokyo, Japan).
Immunoblot analysis. Immunoblot analysis was performed as previously described (21) . Briefly, whole cell lysates were subjected to electrophoresis in 7.5 or 10% SDS-PAGE, and electrophoretically transferred to Immobilon-P nylon membrane (Millipore, Bedford, MA). The membranes were blocked with BlockAce (Dainippon Pharmaceutical, Co. Ltd., Osaka, Japan) for at least 2 h, and probed with the indicated primary antibodies overnight, followed by horseradish peroxidase-conjugated secondary antibodies (Dako, Glostrup, Denmark). Bands were visualized using ECL reagents (Amersham Bioscience, Piscataway, NJ).
Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR).
Isolation of total cellular RNA from cells was performed using RNeasy mini kit (Qiagen, Valencia, CA), and 2 µg of the total cellular RNA was used to synthesize first-strand cDNA by using SuperScript III Reverse Transcriptase Kit (Invitrogen). Quantitative determination of gene expression was performed by real-time PCR on a LightCycler ® 2.0 Instrument (Roche). PCR primer sequences were obtained from following references; human Mcl-1 (22) . The relative change in gene expression compared with untreated conditions was expressed as fold change, calculated by 2 -∆∆Cp method (24) .
Transfection of small interfering RNAs. Silencing of Mcl-1 expression in A549 cells was performed as previously described (19) . Human Mcl-1 Stealth RNAi™ siRNA (HSS181042) was purchased from Invitrogen. Firefly luciferase (GL2) siRNA was obtained from Hokkaido System Science Co. Ltd. (Sapporo, Japan), and used as control siRNA (19) . A549 cells were transfected with siRNAs at a final concentration of 20 nM, using Lipofectamine 2000 reagent. Cells were treated with TRAIL at 24 h after transfection.
Statistical analysis. Data are expressed as mean + SD, and analyzed by Student's two-tailed t-test to determine the significance of differences between groups. A p-value of lower than 0.05 was considered to be significant.
Results

Enhancement of TRAIL-induced apoptosis in human cancer cells by Thai propolis extract and chrysin.
Initially, TRAIL sensitization effect of Thai propolis extract was examined in a TRAIL resistant cell line, A549. Pretreatment with propolis extract (25-100 µg/ml) for 30 min, followed by TRAIL stimuµg/ml) for 30 min, followed by TRAIL stimug/ml) for 30 min, followed by TRAIL stimulation for 24 h, enhanced TRAIL-induced cell death. At the highest propolis concentration test (100 µg/ml), cell viability of the combination treatment was 38%, compared with 63 and 98% viability with propolis alone and TRAIL alone, respectively (Fig. 1A) . Chrysin and tectochrysin were found to be two major constituents of the Thai propolis extract. Chrysin enhanced TRAIL-induced cell death, with cell viability being 47% in the combination treatment, compared to 86 and 92% viability with chrysin alone and TRAIL alone, respectively, while tectochryin did not show significant effect (Fig. 1B) . TRAIL sensitization effect of chrysin was observed in a dose-dependent manner over the tested ranges (20-60 µM) in both A549 and HeLa cell lines, which originated from different organs (Fig. 1C) .
Hallmarks of cells undergoing apoptosis are cleavage of procaspase-3 and poly(ADP-ribose) polymerase (PARP). Massive cell death of A549 and HeLa cells could be observed as early as 3 h after treatment with chrysin/TRAIL combination (Fig. 1D) , concordant with enhancement of apoptosis as clearly shown by increased cleavage of pro-caspase-3 and PARP (Fig. 1E) . Our results revealed that apoptosis-inducing effect of TRAIL was enhanced by chrysin.
TRAIL sensitization effect of chrysin is not mediated by NF-κB inhibition.
In addition to inducing apoptosis signaling, TRAIL and TNFα receptors also activate survival signaling such NF-κB which regulates expression of several anti-apoptotic proteins to counteract the apoptosis signaling (1). Since chrysin was shown to sensitize TNFα-induced apoptosis in human cancer cells by inhibiting NF-κB activation (15), thus, we examined effect of chrysin on TNFα-or TRAIL-induced NF-κB activation in A549/NF-κB stable cell line. Stimulation of TNFα for 3 h induced activation and increased transcriptional activity of NF-κB by 20.8-fold compared to control (Fig. 2A) . TNFα-induced NF-κB activation was diminished by chrysin pretreatment (60 µM), with 79% inhibition observed, while IKK-2 inhibitor pretreatment (10 µM) led complete inhibition ( Fig. 2A) . In contrast, TRAIL stimulation slightly induced NF-κB activation by 1.1-fold, while NF-κB activation was more increased by chrysin alone or chrysin/TRAIL combination treatment, with 1.8-and 1.9-fold induction respectively ( Fig. 2A) . These results indicated that chrysin did not inhibit TRAIL-induced NF-κB activation in A549 cells. Furthermore, inhibition of TRAIL-induced NF-κB activation by IKK-2 inhibitor did not significantly enhance cell death in A549 cells (Fig. 2B) , indicating that inhibition of NF-κB activation is unlikely to be the mechanism of chrysin for TRAIL sensitization.
Glutathione depletion does not contribute to TRAIL sensitization effect of chrysin. Chrysin has been shown to sensitize A549 cells to chemotherapeutic drugs by depleting intracellular glutathione (13, 14) . N-acetylcysteine (NAC), a precursor of glutathione synthesis, has been shown to reverse TRAIL sensitization by curcumin (25) . We evaluated the involvement of glutathione depletion in TRAIL sensitization effect of chrysin by pretreatment of A549 cells with NAC (10 mM) for 2 h, to increase intracellular glutathione level before exposure to TRAIL combination treatment. If the cytotoxic effect of the combination treatment is mediated by glutathione depletion effect, the NAC pretreatment will abolish the cytotoxic effect. The results showed that TRAIL sensitization effect of chrysin was unaffected by NAC pretreatment, but TRAIL sensitization effect of curcumin was potently reversed by NAC pretreatment (Fig. 3) . The results clearly indicated that glutathione depletion does not contribute to the TRAIL sensitization effect of chrysin.
Mcl-1 downregulation mediates TRAIL sensitization effect of chrysin. Many naturally occurring polyphenols enhance TRAIL sensitization through downregulation of anti-apoptotic proteins (26) . We further examined effect of chrysin on levels of several anti-apoptotic proteins, including Mcl-1, Bcl-XL, XIAP, survivin and 14-3-3, in both A549 and HeLa cells. The results showed that, at 3 h after treatment, chrysin alone (60-100 µM) or in combination with TRAIL selectively decreased Mcl-1 protein level, while the levels of other proteins remained unaffected (Fig. 4A) . The dose-dependent decrease in Mcl-1 protein level by chrysin was observed in both A549 and HeLa cell lines (Fig. 4A and B) . Effect of chrysin on another short half-life anti-apoptotic protein, FLIP, was examined compared with Mcl-1. The rapid turnover rate of both proteins in cells is mediated by the proteasome (27) . FLIP has 2 isoforms -FLIP L and FLIP S , but FLIP S was not detected in our cell lines. Chrysin treatment (60 µM) for 3 h decreased Mcl-1 level, while FLIP L levels in both cell lines were not reduced (Fig. 4C) .
To explore the cause of Mcl-1 reduction by chrysin, we determined mRNA level of Mcl-1 gene after treatment by using qRT-PCR. Effect of chrysin on Mcl-1 gene expression was clearly demonstrated, chrysin (60 µM) treatment for 3 h reduced Mcl-1 mRNA level by 52% (Fig. 4D) . The results suggested that modulation of TRAIL sensitivity of cancer cells by chrysin was occurred through downregulation of Mcl-1 gene expression.
Silencing Mcl-1 expression is sufficient to enhances TRAILinduced apoptosis.
To confirm that reduction of Mcl-1 level was able to sensitize cells to TRAIL-induced apoptosis, siMcl-1 transfection was used to silence Mcl-1 expression in A549 cells, while siLuc was used as control siRNA. At 24 h after transfection, the level of Mcl-1 protein was obviously decreased in siMcl-1 transfected cells compared with siLuc transfected cells (Fig. 5A) . After TRAIL stimulation for 3 h, many apoptotic cells were observed in the siMcl-1 transfected cells (Fig. 5B) , correlating with cleavage of pro-caspase-3, while the procaspase-3 cleavage was faintly detected in TRAIL-stimulated siLuc transfected cells (Fig. 5A) . Taken together, the results confirmed that TRAIL sensitization effect of chrysin was mediated by Mcl-1 downregulation. Thus, we further investigated mechanism of Mcl-1 modulation by chrysin.
Chrysin downregulates Mcl-1 expression through inhibiting STAT3 tyrosine phosphorylation.
Mcl-1 gene expression is regulated by multiple signaling pathways, including STAT3, Akt and p38 pathways (28) . We examined the effects of chrysin treatment (60-100 µM) for 3 h, either alone or in combination with TRAIL, on several survival signaling pathways including STAT3, Akt, ERK, p38 and NF-κB. Among the selected pathways, marked inhibition was obtained only in constitutive STAT3 tyrosine phosphorylation (Tyr 705 ), in both A549 and HeLa cells (Fig. 6A) . Tyr 705 phosphorylation of STAT3 is necessary for DNA-binding and transcriptional activity of STAT3 (29) . Correlation between decreased STAT3 tyrosine phosphorylation and Mcl-1 downregulation was observed in A549 cells treated with chrysin in a time-dependent manner, while Akt phosphorylation was not affected within the time-course measured (Fig. 6B) . The results suggested that STAT3 was the target of chrysin for modulating level of Mcl-1 expression.
STAT3 specific inhibitor decreases Mcl-1 level and enhances TRAIL-induced cell death.
To confirm that Mcl-1 expression is regulated by STAT3, A549 cells was treated with a specific inhibitor of STAT3 (cucurbitacin-I) for 3 h, the result showed that the STAT3 inhibitor decreased both STAT3 tyrosine phosphorylation and Mcl-1 level (Fig. 7A) . Furthermore, the STAT3 inhibitor enhanced TRAIL-induced cell death (Fig. 7B ) in a dose-dependent manner, similar to that observed with chrysin treatment. Collectively, our results indicated that the TRAIL Figure 2 . NF-κB inhibition does not mediate the TRAIL sensitization effect of chrysin. (A) Effect of chrysin on NF-κB transcriptional activity. A549 cells stably transfected with NF-κB reporter plasmid were pretreated with chrysin (60 µM) or IKK-2 inhibitor (10 µM) for 30 min, and further stimulated with TNFα (30 ng/ml) or TRAIL (100 ng/ml) for 3 h. NF-κB transcriptional activity was then determined by luciferase assay. (B) NF-κB inhibitor does not enhance TRAIL-induced cell death in A549. The cells were pretreated with test compound for 30 min, and further incubated in the presence or absence of TRAIL (100 ng/ml) for 24 h. Cell viability was determined by MTT assay, and significant difference between with TRAIL and without TRAIL is shown by ** p<0.01. Figure 3 . Effect of antioxidant pretreatment on TRAIL sensitization by chrysin. Cells were pretreated with NAC, glutathione precursor (10 mM) for 2 h, then treated with chrysin or curcumin for 30 min, and further incubated in the presence or absence of TRAIL for 24 h. Cell viability was determined by MTT assay. Data are expressed as mean ± SD from three independent experiments, and significant difference between groups are shown by ** p<0.01. sensitization effect of chrysin was mediated by Mcl-1 downregulation through inhibition of constitutive STAT3 tyrosine phosphorylation.
Discussion
Induction of apoptosis via TRAIL receptor is a promising targeted therapy, but this strategy also faces a similar problem to the use of other chemotherapeutic drugs, because TRAIL resistance is found in variety of cancers. The TRAIL sensitization effect of chrysin was recently reported (16) , but the underlying mechanism has not been elucidated until now. In the present study, we demonstrated a novel mechanism for apoptosis-sensitizing effect of chrysin that overcomes TRAIL resistance of cancer cells. We demonstrated that downregulation of Mcl-1 anti-apoptotic protein by STAT3 inhibition is the mechanism for chrysin in expression regulation of STAT3 target genes coordinates the findings of Polier et al (37) and our results to depict the molecular details of the mechanism of Mcl-1 downregulation by chrysin via STAT3 inhibition. Chrysin has been shown to inhibit Akt phosphorylation in cancer cells (11, 42) . However, we did not observe inhibition of Akt phosphorylation by chrysin within the first 3 h after treatment (Fig. 6A) , when the TRAIL-induced apoptosis had already progressed (Fig. 1E ), and Mcl-1 level and STAT3 tyrosine phosphorylation were concomitantly decreased (Fig. 6B) . Our results suggested that Akt inhibition was not the primary mechanism responsible for TRAIL sensitization effect of chrysin in our cellular models.
Although, inhibition of NF-κB activation was the mechanism of chrysin for enhancement of TNFα-induced apoptosis in HCT116 colorectal cancer cells (15), chrysin did not inhibit TRAIL-induced NF-κB activation in A549 cells. Moreover, chrysin alone slightly increased NF-κB transcriptional activity ( Fig. 2A) , which was also observed in HeLa cells (data not shown). This phenomenon is consistent with a previous report showing that, in HeLa cells, chrysin induced DNA binding activity of p65 NF-κB which could be reversed by NAC pretreatment (43) , indicating involvement of a glutathione depletion effect in the increased DNA binding activity of NF-κB by chrysin.
Our results clearly showed that NAC pretreatment did not abolish the TRAIL sensitization effect of chrysin, in contrast to curcumin, another glutathione depleting agent (Fig. 3) , suggesting that the glutathione depletion effect did not contribute to TRAIL sensitization effect of chrysin. A recent report showed the ability of chrysin to activate AMP-activated protein kinase (AMPK), and this AMPK activation mediated enhancement of doxorubicin cytotoxicity in A549 cells (44) . The report also demonstrated that AMPK activation led to inhibition of Akt phosphorylation and NAC pretreatment could reverse the AMPK activation. We suggest that the AMPK activation is unlikely to be involved in TRAIL sensitization effect of chrysin, because our results revealed that NAC pretreatment did not reverse TRAIL sensitization effect of chrysin (Fig. 3) . We suggest that mechanisms of the biological effects of chrysin can be divided into glutathione depletion-dependent and -independent mechanisms.
In conclusion, as depicted in Fig. 8 , we have demonstrated that chrysin can inhibit constitutive STAT3 activation, resulting in Mcl-1 downregulation, and this activity underlies the overcoming TRAIL resistance of cancer cells by chrysin. Our study suggests the potential of chrysin for use as a TRAIL sensitizer. 
